Computed tomography in cystic fibrosis lung disease: a focus on radiation exposure

被引:0
作者
Stella Joyce
Brian W. Carey
Niamh Moore
David Mullane
Michael Moore
Mark F. McEntee
Barry J. Plant
Michael M. Maher
Owen J. O’Connor
机构
[1] University College Cork,Department of Radiology, School of Medicine
[2] Cork University Hospital,Department of Radiology
[3] University College Cork,Department of Radiography
[4] Cork University Hospital,Department of Paediatrics
[5] Cork University Hospital,Department of Medicine
[6] University College Cork,APC Microbiome Institute
来源
Pediatric Radiology | 2021年 / 51卷
关键词
Adolescents; Children; Computed tomography; Cystic fibrosis; Ionising radiation; Lung disease;
D O I
暂无
中图分类号
学科分类号
摘要
Thoracic computed tomography (CT) is the imaging reference method in the diagnosis, assessment and management of lung disease. In the setting of cystic fibrosis (CF), CT demonstrates increased sensitivity compared with pulmonary function tests and chest radiography, and findings correlate with clinical outcomes. Better understanding of the aetiology of CF lung disease indicates that even asymptomatic infants with CF can have irreversible pulmonary pathology. Surveillance and early diagnosis of lung disease in CF are important to preserve lung parenchyma and to optimise long-term outcomes. CF is associated with increased cumulative radiation exposure due to the requirement for repeated imaging from a young age. Radiation dose optimisation, important for the safe use of CT in children with CF, is best achieved in a team environment where paediatric radiologists work closely with paediatric respiratory physicians, physicists and radiography technicians to achieve the best patient outcomes. Despite the radiation doses incurred, CT remains a vital imaging tool in children with CF. Radiologists with special interests in CT dose optimisation and respiratory disease are key to the appropriate use of CT in paediatric imaging. Paediatric radiologists strive to minimise radiation dose to children whilst providing the best possible assessment of lung disease.
引用
收藏
页码:544 / 553
页数:9
相关论文
共 159 条
[1]  
Debray D(2011)Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease J Cyst Fibros 10 S29-S36
[2]  
Kelly D(2012)Cystic fibrosis drug Vertex’s latest triumph Nat Biotechnol 30 201-202
[3]  
Houwen R(2011)A CFTR potentiator in patients with cystic fibrosis and the G551D mutation N Engl J Med 365 1663-1672
[4]  
Ledford H(2016)Lumacaftor/ivacaftor combination for cystic fibrosis patients homozygous for Phe508del-CFTR Drugs Today (Barc) 52 229-237
[5]  
Ramsey BW(2012)Radiological imaging in cystic fibrosis: cumulative effective dose and changing trends over 2 decades Chest 141 1575-1583
[6]  
Davies J(2018)CORK study in cystic fibrosis: sustained improvements in ultra-low-dose chest CT scores after CFTR modulation with Ivacaftor Chest 153 395-403
[7]  
McElvaney NG(2005)High-resolution computed tomography imaging of airway disease in infants with cystic fibrosis Am J Respir Crit Care Med 172 1133-1138
[8]  
Zhang W(2012)Progression of early structural lung disease in young children with cystic fibrosis assessed using CT Thorax 67 509-516
[9]  
Zhang X(2008)Multiple-breath inert gas washout and spirometry versus structural lung disease in cystic fibrosis Thorax 63 129-134
[10]  
Zhang YH(2004)Progressive damage on high resolution computed tomography despite stable lung function in cystic fibrosis Eur Respir J 23 93-97